Equities analysts expect Icon Plc (NASDAQ:ICLR) to announce $1.41 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Icon’s earnings, with the highest EPS estimate coming in at $1.43 and the lowest estimate coming in at $1.38. Icon posted earnings of $1.26 per share during the same quarter last year, which indicates a positive year over year growth rate of 11.9%. The business is expected to announce its next earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Icon will report full-year earnings of $5.37 per share for the current year, with EPS estimates ranging from $5.34 to $5.38. For the next year, analysts anticipate that the business will report earnings of $5.97 per share, with EPS estimates ranging from $5.87 to $6.06. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Icon.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. Icon had a return on equity of 28.42% and a net margin of 16.37%. The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company earned $1.19 earnings per share.

A number of equities research analysts recently commented on the company. Barclays lifted their target price on Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a report on Friday, October 27th. SunTrust Banks reaffirmed a “buy” rating and set a $138.00 target price on shares of Icon in a report on Sunday, October 29th. Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Jefferies Group reaffirmed a “buy” rating and set a $122.00 target price on shares of Icon in a report on Tuesday, September 12th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $123.00 target price on shares of Icon in a report on Thursday, October 12th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $121.00.

A number of large investors have recently made changes to their positions in ICLR. Acrospire Investment Management LLC lifted its holdings in Icon by 20.1% in the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 200 shares during the period. Parallel Advisors LLC lifted its holdings in Icon by 20.7% in the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 217 shares during the period. SG Americas Securities LLC acquired a new position in Icon in the third quarter valued at approximately $148,000. Sheaff Brock Investment Advisors LLC acquired a new position in Icon in the second quarter valued at approximately $208,000. Finally, Commonwealth Equity Services Inc acquired a new position in Icon in the third quarter valued at approximately $208,000. 89.95% of the stock is owned by institutional investors.

Shares of Icon (NASDAQ ICLR) traded up $0.48 during midday trading on Friday, reaching $114.00. The company’s stock had a trading volume of 251,117 shares, compared to its average volume of 281,123. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. Icon has a fifty-two week low of $73.76 and a fifty-two week high of $124.48. The firm has a market capitalization of $6,160.00, a P/E ratio of 21.88, a PEG ratio of 1.76 and a beta of 0.61.

COPYRIGHT VIOLATION NOTICE: “Icon Plc (ICLR) Expected to Post Earnings of $1.41 Per Share” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/17/icon-plc-iclr-expected-to-post-earnings-of-1-41-per-share.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.